Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ...

President Donald Trump on Thursday announced deals with pharmaceutical giants Novo Nordisk and Eli Lilly that would cut the cost of the lowest doses of their in-demand weight-loss drugs, lowering the ...

The White House unveiled agreements with pharma giants Eli Lilly and Company and Novo Nordisk to offer GLP-1's Zepbound, orforglipron, Ozempic and Wegovy through the prescription digital marketplace ...

Eli Lilly and Novo Nordisk have become the latest pharma giants to strike price-reduction deals with the White House, agreeing to sell their weight loss drugs at cut-rate prices to patients in the U.S ...

Eli Lilly and Novo Nordisk will lower prices for GLP-1 receptor agonists, aligning with the Most Favored Nation executive order to address US drug pricing disparities. Novo Nordisk's semaglutide ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Lilly's six existing Gateway ...

We recently published 10 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) continues to be one of ...

Eli Lilly and Company LLY will report its third-quarter 2025 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $16.01 billion and $6.02 per ...

Eli Lilly (NYSE:LLY) on Friday reported plans to acquire Adverum Biotechnologies (NASDAQ:ADVM) and its lead gene therapy candidate, Ixo-vec, sending Adverum shares soaring in premarket trading. Under ...

You may know Hassan Emilio Kabande Laija as Peso Pluma, the raspy-voiced Mexican singer and rapper who’s been a chart-topping success since he hit the scene in 2020. He’s now part of the lineup at the ...

Mounjaro and Zepbound have helped boost the company's market cap. New data indicate these drugs do more than just help patients lose weight, contributing to potentially lowering risks to hearts and ...